Zheng Yantao, Wu Gang, Chen Limei, Zhang Ying, Luo Yuwei, Zheng Yong, Hu Fengjun, Forouzanfar Tymor, Lin Haiyan, Liu Bin
Emergency Department, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Department of Oral Implantology and Prosthetic Dentistry, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam (UvA) and Vrije Universiteit Amsterdam (VU), Amsterdam, Netherlands.
Bioact Mater. 2020 Sep 19;6(3):627-637. doi: 10.1016/j.bioactmat.2020.08.026. eCollection 2021 Mar.
Brain tissues that are severely damaged by traumatic brain injury (TBI) is hardly regenerated, which leads to a cavity or a repair with glial scarring. Stem-cell therapy is one viable option to treat TBI-caused brain tissue damage, whose use is, whereas, limited by the low survival rate and differentiation efficiency of stem cells. To approach this problem, we developed an injectable hydrogel using imidazole groups-modified gelatin methacrylate (GelMA-imid). In addition, polydopamine (PDA) nanoparticles were used as carrier for stromal-cell derived factor-1 (SDF-1α). GelMA-imid hydrogel loaded with PDA@SDF-1α nanoparticles and human amniotic mesenchymal stromal cells (hAMSCs) were injected into the damaged area in an cryogenic injury model in rats. The hydrogel had low module and its average pore size was 204.61 ± 41.41 nm, which were suitable for the migration, proliferation and differentiation of stem cells. cell scratch and differentiation assays showed that the imidazole groups and SDF-1α could promote the migration of hAMSCs to injury site and their differentiation into nerve cells. The highest amount of nissl body was detected in the group of GelMA-imid/SDF-1α/hAMSCs hydrogel in the model. Additionally, histological analysis showed that GelMA-imid/SDF-1α/hAMSCs hydrogel could facilitate the regeneration of regenerate endogenous nerve cells. In summary, the GelMA-imid/SDF-1α/hAMSCs hydrogel promoted homing and differentiation of hAMSCs into nerve cells, and showed great application potential for the physiological recovery of TBI.
因创伤性脑损伤(TBI)而严重受损的脑组织几乎无法再生,这会导致形成空洞或形成胶质瘢痕修复。干细胞疗法是治疗TBI所致脑组织损伤的一种可行选择,然而,其应用受到干细胞低存活率和分化效率的限制。为了解决这个问题,我们使用咪唑基团修饰的甲基丙烯酸明胶(GelMA-imid)开发了一种可注射水凝胶。此外,聚多巴胺(PDA)纳米颗粒被用作基质细胞衍生因子-1(SDF-1α)的载体。将负载有PDA@SDF-1α纳米颗粒和人羊膜间充质基质细胞(hAMSCs)的GelMA-imid水凝胶注射到大鼠低温损伤模型的损伤区域。该水凝胶模量低,平均孔径为204.61±41.41nm,适合干细胞的迁移、增殖和分化。细胞划痕和分化试验表明,咪唑基团和SDF-1α可促进hAMSCs向损伤部位迁移并分化为神经细胞。在该模型中,GelMA-imid/SDF-1α/hAMSCs水凝胶组检测到的尼氏体数量最多。此外,组织学分析表明,GelMA-imid/SDF-1α/hAMSCs水凝胶可促进内源性神经细胞的再生。总之,GelMA-imid/SDF-1α/hAMSCs水凝胶促进了hAMSCs归巢并分化为神经细胞,在TBI的生理恢复方面显示出巨大的应用潜力。